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ABSTRACT 
 
Inflammatory pain sensitization is initiated by prostaglandin-induced phosphorylation of α3 glycine 
receptors (GlyRs) that are specifically located in inhibitory synapses on spinal pain sensory neurons. 
Phosphorylation reduces the magnitude of glycinergic synaptic currents, thereby disinhibiting nociceptive 
neurons. Although α1 and α3 subunits are both expressed on spinal nociceptive neurons, α3 is a more 
promising therapeutic target as its sparse expression elsewhere implies a reduced risk of side-effects. Here 
we compared glycine-mediated conformational changes in α1 and α3 GlyRs to identify structural differences 
that might be exploited in designing α3-specific analgesics. Using voltage-clamp fluorometry, we show that 
glycine-mediated conformational changes in the extracellular M2-M3 domain were significantly different 
between the two GlyR isoforms. Using a chimeric approach, we found that structural variations in the 
intracellular M3-M4 domain were responsible for this difference. This prompted us to test the hypothesis that 
phosphorylation of S346 in α3 GlyR might also induce extracellular conformation changes. We show using 
both voltage-clamp fluorometry and pharmacology that Ser346 phosphorylation elicits structural changes in 
the α3 glycine-binding site. These results provide the first direct evidence for phosphorylation-mediated 
extracellular conformational changes in pentameric ligand-gated ion channels, and thus suggest new loci for 
investigating how phosphorylation modulates structure and function in this receptor family. More 
importantly, by demonstrating that phosphorylation alters α3 GlyR glycine-binding site structure, they raise 
the possibility of developing analgesics that selectively target inflammation-modulated GlyRs.  
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INTRODUCTION 
 
Members of the pentameric ligand-gated ion channel (pLGIC) receptor family mediate fast synaptic 
transmission in the nervous system. The cation-permeable nicotinic acetylcholine receptor (nAChR) is the 
most intensively studied member of this family, with other members including the anion-permeable glycine 
and GABA type-A receptors (GlyRs and GABAARs) and the cation-permeable serotonin type-3 receptor (5-
HT3R)1. Functional pLGICs comprise an assembly of five homologous membrane-spanning subunits 
arranged symmetrically around a central pore. All subunits incorporate large N-terminal ligand-binding 
domains that form neurotransmitter-binding sites at the interface of adjacent domains. The eponymous 
extracellular Cys-loop is conserved among eukaryotic members of this family. In addition, GlyRs 
incorporate a second Cys-loop that forms the C loop ligand-binding domain that is crucial for glycine 
binding2. The ligand-binding domain is followed by four transmembrane α-helices, termed M1-M4, that 
each span the entire thickness of the cell membrane. Each subunit contributes an M2 domain to the lining of 
the axial water-filled pore. To facilitate comparison of pore-lining residues between different pLGIC 
members, a common M2 residue numbering system is used which assigns 1’ and 19’ to the innermost and 
outermost pore-lining residues, respectively. The M1, M2 and M3 domains are connected by short loops. 
The intracellular domain linking M3 and M4 varies considerably in both length and amino acid sequence 
among different pLGIC subunits.  
   Although GlyRs are best known for mediating inhibitory neurotransmission in reflex circuits of the spinal 
cord, they also mediate inhibitory neurotransmission onto spinal nociceptive neurons in superficial laminae 
of the spinal cord dorsal horn. GlyR α3 subunits, which are otherwise sparsely distributed, are abundantly 
expressed in these synapses3. Chronic inflammatory pain sensitization is caused in part by a prostaglandin E2 
(PGE2)-mediated activation of protein kinase A (PKA), which in turn phosphorylates α3 GlyRs at S346, 
leading to a diminution of glycinergic synaptic current magnitude 3,4. This disinhibits spinal nociceptive 
sensory neurons resulting in chronic inflammatory pain sensitization. Due to their sparse distribution outside 
the spinal cord dorsal horn, α3 GlyRs have emerged as preferred therapeutic targets for chronic pain5,6, and 
agents that potentiate α3 GlyRs have been shown to exhibit analgesic efficacy in animal models of chronic 
inflammatory pain7.  
   Our original aim was to compare glycine-induced conformational changes in α1 and α3 GlyRs in an 
attempt to identify structural differences that could be exploited in the design of α3-specific potentiators. To 
achieve this, we employed voltage-clamp fluorometry (VCF) to quantitate conformational changes occurring 
in the immediate vicinity of residues labeled with environmentally-sensitive fluorophores. Initially, we 
probed glycine-induced conformational changes at a fluorescent reporter attached at the external end (R271 
or R19’) of the M2 pore-lining domain. This revealed differences in glycine-induced conformations in α1 
and α3 GlyRs that, to our surprise, were due to structural variations in their M3-M4 domains. This prompted 
us to investigate whether PKA-induced phosphorylation of S346 (in the α3 GlyR M3-M4 domain) may also 
produce extracellular conformational changes. Phosphorylation of S346 was found to induce conformational 
changes not only at the external end of M2, but also in the glycine-binding site.  
RESULTS AND DISCUSSION 
 
   We employed VCF to compare glycine-induced conformational changes in α1 and α3 receptors in an 
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attempt to identify structural differences that could be exploited in the design of α3-specific potentiators as 
analgesics. For these studies we employed the GlyR human α1 and rat α3L subunit cDNAs (Fig. S1) with 
Uniprot accession numbers of P23415-2 (i.e., isoform b) and P24524, respectively. Both constructs 
incorporated the C41A mutation that eliminated the sole uncrosslinked extracellular sulfhydryl group. The 
C41A mutation has no effect on receptor function8,9. Constructs incorporating only this mutation are termed 
wild type (WT). We initially compared the glycine-induced fluorescence responses of a 
methanethiosulfonate-rhodamine (MTSR) reporter covalently attached to R19’C in the α1 and α3 GlyRs. 
Although the R19’C mutation impairs the glycine gating efficacy of the α1 GlyR8-10, we employed it here for 
two reasons, First, R19’ forms part of the M2-M3 loop which is known to be intimately involved in receptor 
gating11,12. Hence, if α1 and α3 GlyRs exhibit distinct quaternary structures, this difference should be 
reflected in their gating mechanisms and hence R19’C should be a promising location for detecting these. 
Second, R19’C is the only known gating site that when fluorescently labeled gives a glycine-induced 
fluorescence change (ΔF) large enough to be quantitatively analysed9. The maximum glycine-induced 
fluorescence response (ΔFmax) in the MTSR-labeled α1-R19’C GlyR is about 20 %9. By comparison, 
application of a saturating (30 mM) glycine concentration to MTSR-labeled α3-R19’C GlyRs elicited a 
∆Fmax of 5.1 ± 1.0 % (n = 13). As no detectable ∆F was ever observed in wild type (WT) MTSR-labeled α1-
WT or α3-WT GlyRs (Table S1), we conclude that the α3-R19’C GlyR is specifically labeled by MTSR.  
   A structural model of an α3 GlyR subunit displaying the location of R19’ and the M2-M3 loop is presented 
in Fig. 1A. As previously observed for the α1-R19’C GlyR9, glycine current (ΔI) and ΔF dose-response 
relationships were almost overlapping in α3-R19’C GlyRs (Fig. 1B, C). Indeed, using a paired t-test, the 
mean glycine ΔI half-maximal concentration (EC50) of 1740 ± 270 µM (n = 13) was not significantly 
different from the mean glycine ΔF EC50 of 1340 ± 210 µM (n = 13). However, both values were 
significantly larger than the corresponding α3-WT GlyR ΔI glycine EC50 value (74 ± 2 µM, n = 6) using an 
unpaired t-test (P < 0.001 for both). Sample recordings of ΔFmax responses from MTSR-labeled α3-R19’C 
GlyRs suggested that they were smaller in magnitude and slower to decay to baseline than those recorded 
from MTSR-labeled α1-R19’C GlyRs (Fig. 1D). Averaged results confirmed that ΔFmax responses from α3-
R19’C GlyRs were significantly reduced in magnitude, although their saturating current magnitude (ΔImax) 
values were not significantly different (P > 0.08 by unpaired t-test) (Fig. 1E). We quantified ΔF decay rates 
by determining the ratio of the ΔFmax half-decay time to the ΔImax half-decay time in the same oocyte to 
control for possible differences in ΔImax decay rate between receptor subtypes. As shown in Fig. 1F, ΔFmax did 
indeed decay at a significantly slower rate in MTSR-labeled α3-R19’C GlyRs relative to MTSR-labeled α1-
R19’C GlyRs. These differences were surprising because the amino acid sequences of α1 and α3 subunits 
are identical in all domains that are likely to come into contact with a rhodamine attached at the 19’C 
position.  
   Due to this unexpected finding, we compared the effects of a variety of pharmacological modulators on 
ΔFmax responses of MTSR-labeled α1-R19’C and α3-R19’C GlyRs. Although taurine and β-alanine are both 
very low efficacy agonists of α3-R19’C GlyRs, they elicit disproportionately large ΔF increases9. Consistent 
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with this, although saturating taurine evoked no ∆I in α3-R19’C GlyRs (Fig. S2A), it evoked mean ΔFmax 
near 25 % of that produced by a saturating glycine concentration (Fig. S2B, Table S1). Similarly, saturating 
β-alanine evoked a very small ΔImax but a large ∆Fmax that was ~50 % of that produced by saturating glycine 
(Fig. S2A and B, Table S1). To facilitate comparison with glycine-mediated responses, Fig. S1B shows 
mean ∆I and ∆F concentration-response relationships for glycine, β-alanine and taurine with all averaged 
ΔImax, ΔFmax, EC50 and Hill coefficient (nH) values summarized in Table S1. All variables corresponded 
closely to those recorded from MTSR-labeled α1-R19’C GlyRs under similar experimental conditions9. 
   Ivermectin, which irreversibly activates α1 and α3 GlyRs13,14, was previously shown to activate MTSR-
labeled α1-R19’C GlyRs without inducing a detectable ΔF9. Here we found that saturating (15 µM) 
ivermectin evoked slowly activating currents in MTSR-labeled α3-R19’C GlyRs although detectable ΔF was 
observed (Fig. S2C). 
   Finally, we compared the effects of the allosteric inhibitor, picrotoxin, and the classical competitive 
antagonist, strychnine. When applied alone, picrotoxin did not evoke significant ∆I or ∆F changes in oocytes 
expressing MTSR labeled α3-R19’C GlyRs (Fig. S2D). However, when co-applied with EC50 glycine, 50 
µM picrotoxin potently inhibited the current, although the ∆F increased significantly (17.3 ± 2.7 %, n=6). 
Strychnine also had no effect when applied alone, but significantly reduced ΔF by 48.7 ± 7.6 % (n=6) when 
co-applied with EC50 glycine (Fig. S2E). The effects of both drugs on the direction of ΔF responses are 
consistent with those observed at MTSR-labeled α1-R19’C GlyRs9. From all these results, we infer that 
rhodamine labels attached to α1-R19’C and α3-R19’C GlyRs respond similarly to a variety of 
pharmacological manipulations, with the main difference being that α3-R19’C GlyRs exhibit smaller 
glycine-induced ΔFmax values and slower ΔF decay rates. 
   To isolate the domain responsible for the differential ΔF response characteristics, we initially generated a 
series of six chimeras, labeled Chi1-Chi6 as shown in Fig. 2A. Each chimera was constructed from three 
variable modules: a ligand-binding domain, an M1-M3 transmembrane bundle plus large intracellular M3-
M4 domain, and an M4 plus short C-terminal tail. A cysteine was introduced at the R19’C position of each 
chimera. The cDNAs for all chimeras were subcloned into the pGEMHE oocyte expression vector and 
functionally expressed in oocytes. Glycine ΔI and ΔF dose-response relationships were measured for all six 
chimeras and all mean glycine EC50, nH, ΔImax and ΔFmax values are summarized in Table S2. Mean ΔImax 
values were similar for all six chimeras (Fig. 2B). However, the ΔF/ΔI half-decay time ratios and ∆Fmax 
values of three chimeras (Chi3, Chi5, Chi6) were all similar to those of α1-R19’C GlyRs whereas those of 
the other three chimeras (Chi1, Chi2, Chi4) were significantly different from α1-R19’C GlyRs but similar to 
those of α3-R19’C GlyRs (Fig. 2C, D). These results indicate that the differences in ΔF response 
characteristics can be transposed from the α1 to the α3 GlyR (and vice versa) by transposing the M1-M3 
transmembrane bundle plus M3-M4 domain.  
   The M1-M3 transmembrane bundle amino acid sequences are very highly conserved between α1 and α3 
GlyRs, with nonconserved residues existing only at I240 and G254 of the α1 subunit (residue numbering is 
the same for both subunits). The corresponding residues in the α3 GlyR are valine and alanine. To determine 
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whether either of these was responsible for the differential ΔF response, we investigated the α1-R19’C-
I240V, α1-R19’C-G254A, α3-R19’C-V240I and α3-R19’C-A254G double mutant GlyRs. However, as 
these mutations produced no significant change in ΔF properties, we generated another two chimeras (ChiA 
and ChiB, Fig. 2A) where only the M3-M4 domains were exchanged. The mean glycine EC50, nH, ΔImax and 
ΔFmax values for ChiA and ChiB receptors, measured both before and after MTSR-labeling, are summarized 
in Table S2. Mean ΔImax and ΔFmax responses of both chimeras, plus those of the original α1-R19’C and α3-
R19’C GlyRs, are shown in Fig. 2B and C. The ΔImax of labeled ChiA was significantly reduced relative to 
those of both α1-R19’C and α3-R19’C GlyRs, possibly implying impaired surface expression. Nevertheless, 
the results for ChiB unequivocally indicate that transposing the M3-M4 domain from the α1-R19'C into the 
α3-R19'C GlyR produces an increased ΔFmax similar to that of the α1-R19'C GlyR (Fig. 2 C,D). Similarly, 
analysis of the ΔF/ΔI half-decay time ratios indicated that this value can also be transferred between 
receptors by transferring their M3-M4 domains (Fig. 2D). Thus, these results indicate that the primary 
structure of the M3-M4 domain influences tertiary structure in the immediate vicinity of a rhodamine label 
attached to R19’C (Fig. 1A).  
     We next hypothesized that dynamic changes in M3-M4 loop conformation may also influence receptor 
conformation near R19’C. A PKA phosphorylation site has been identified at S346 in the α3 GlyR M3-M4 
domain3. To determine whether phosphorylation of this site alters the microenvironment of a rhodamine 
attached to α3-R19’C, we investigated the effects of two mutations to this residue: S346G to eliminate the 
PKA site and S346E to mimic phosphorylation. The mean glycine EC50, nH, ΔImax and ΔFmax values for the 
unlabeled and MTSR-labeled α3-R19’C-S346E and α3-R19’C-S346G double mutant GlyRs are summarized 
in Table S2. The mean ΔImax and ΔFmax values presented in Fig. 3A indicate that ΔImax was not significantly 
affected by either mutation, suggesting no effect on surface expression levels. However, the mean ΔFmax was 
significantly reduced in α3-R19’C-S346E GlyRs (Fig. 3A). Moreover, the ΔF/ΔI half-decay time ratio was 
significantly faster in the α3-R19’C-S346G GlyR than in the α3-R19’C or α3-R19’C-S346E GlyRs (Fig. 
3B). Thus, the phosphorylation-mimicking S346E mutation shifted both ΔF characteristics (i.e., peak 
magnitude and decay rate) from α1-like to α3-like, whereas eliminating the site (i.e., S346G) produced the 
reverse trend. From this result, we hypothesized that phosphorylation should reduce ΔFmax and possibly also 
prolong the ΔF half-decay time in MTSR-labeled α3-R19’C GlyRs.  
   We tested this directly by treating α3-R19’C GlyRs with 20 µM forskolin for 15 min to phosphorylate 
S346. As shown in the sample recording in Fig. 3C, forskolin reversibly inhibited the ΔF induced by EC50 
glycine in α3-R19’C GlyRs. A control experiment revealed that forskolin produced no significant change in 
ΔF magnitude in phosphorylation-deficient α3-R19’C-S346G GlyRs (Fig. 3D), ruling out the possibility of 
non-specific forskolin effects on ΔF. Similarly, application of 20 µM forskolin to α1-R19’C GlyRs produced 
percentage changes in ΔImax and ΔFmax of 105 ± 8 % and 95 ± 11 % (both n = 20), neither of which was 
significant using a paired t-test (P > 0.1 for both). A control dimethyl sulfoxide application to α3-R19’C 
GlyRs revealed that the incomplete recovery of the ΔF response following forskolin treatment was either a 
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time- or solvent-dependent effect (Fig. 3E, left), most likely representing fluorophore bleaching. As the EC50 
glycine ΔI magnitude remained constant throughout each experiment (Fig. 3C-E), we can rule out an effect 
of phosphorylation on GlyR surface expression levels or glycine sensitivity. Averaged results shown in Fig. 
3E (center and right panels) confirmed that forskolin inhibited the ΔF response of α3-R19’C GlyRs by ~50 
%, but had no effect on α3-R19’C-S346G GlyRs. Together, these results indicate that phosphorylation of 
S346 induced a conformational change in the immediate vicinity of the rhodamine attached to R19’C in the 
α3 GlyR. The direction of this ΔF change is in accordance with that elicited by the phosphorylation-
mimicking S346E mutation. 
   As phosphorylation induces a conformation change in or around the M2-M3 loop, we hypothesized that it 
may induce a global conformational change that propagates to the glycine-binding site. To test this, we 
investigated the effects of forskolin on glycine- and strychnine-induced ΔF responses in α3-N203C GlyRs 
that had been labeled by the sulfhydryl-reactive 2-((5(6)-tetramethylrhodamine)carboxylamino)ethyl 
methanethiosulfonate (MTS-TAMRA). There were three reasons for choosing this site. First, N203 lies at 
the ‘tip’ of the loop C glycine-binding domain (Fig. 1A) that is thought to close around the agonist as it binds 
in its subunit interface pocket15-17. Second, MTS-TAMRA-labeled α1-N203C GlyRs elicit large ΔFs (>40 %) 
in response to the binding of either glycine or strychnine18. Third, unlike R19’C, the N203C mutation does 
not affect glycine sensitivity18. We first quantified the glycine ΔI and ΔF dose-response relationships in 
unlabeled and MTS-TAMRA-labeled α3-N203C and α3-N203C-S346G GlyRs, with all mean glycine EC50, 
nH, ΔImax and ΔFmax values summarized in Table S3. Both mutants exhibited similar ΔImax values which were 
not affected by MTS-TAMRA labeling. However, ΔFmax values were significantly larger in labeled α3-
N203C-S346G GlyRs than in labeled α3-N203C GlyRs (7.1 ± 0.5 vs 4.0 ± 0.4 %, p < 0.05 by unpaired t-
test, n=5 oocytes each). The ΔFmax values induced by saturating (10 µM) strychnine were also significantly 
larger in α3-N203C-S346G GlyRs (8.4 ± 0.2 vs 5.4 ± 0.3 %, p < 0.001 by unpaired t-test, n=5 oocytes each). 
   To determine whether phosphorylation induces a conformational change in the vicinity of a label attached 
to N203C, we tested the effects of a 15 min application of 20 µM forskolin on MTS-TAMRA-labeled α3-
N203C and α3-N203C-S346G GlyRs. As shown in Fig. 4A and B, forskolin reversibly reduced both 
glycine- and strychnine-mediated ΔFmax responses in labeled α3-N203C GlyRs. Non-specific effects were 
eliminated on the grounds that forskolin had no significant effect on strychnine-mediated ΔFmax responses in 
α3-N203C-S346G GlyRs (Fig. 4C). Forskolin did, however, have a small but statistically significant effect 
on glycine- mediated ΔFmax responses in α3-N203C-S346G GlyRs (Fig. 4C, right). We thus infer that 
phosphorylation of S346 induces a conformational change in or near the α3 GlyR glycine-binding site.  
   We next investigated whether the rhodamine attached to N203C could detect molecular changes occurring 
within the glycine-binding pocket. For this we employed two β-carboline derivatives, harmane and 6-
methoxyharmalan, that differ in structure only by a methyoxy group at the C6 position (Fig. S3A). These 
compounds, which are competitive antagonists of glycine, are predicted to bind in the glycine-binding site 
pocket in almost identical orientations19. Saturating (200 µM) concentrations of both β-carbolines elicited ΔF 
decreases in MTS-TAMRA-labeled α3-N203C GlyRs (Fig. S3B), with the average ΔFmax induced by 6-
methoxyharmalan being significantly larger than that induced by harmane (-3.7 ± 0.4 vs -1.0 ± 0.04 %, p < 
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0.05 by unpaired t-test, n=5 oocytes each). Moreover, forskolin treatment inhibited the 6-methoxyharmalan-
mediated ΔFmax, although it had no effect on that produced by harmane (Fig. S3B, D). Differential responses 
were also observed in α3-N203C-S346G GlyRs, with 6-methyoxyharmalan and harmane eliciting ΔFmax 
values of -4.5 ± 0.5 and +0.6 ± 0.1 %, respectively (P < 0.05 by unpaired t-test, n = 5 oocytes each). As 
expected, forskolin elicited either insignificant, or small but significant, effects on the ΔFmax responses 
elicited by either compound in phosphorylation-deficient α3-N203C-S346G GlyRs (Fig. S3C, D). These 
data indicate that a fluorophore attached to N203C successfully reports the addition of a small methoxy 
moiety into the glycine-binding pocket.   
   We then applied the same procedure to investigate the competitive antagonist, tropisetron, which is 
structurally unrelated to the β-carbolines (Fig. S3A) but also binds in the glycine-binding pocket20,21. In the 
MTS-TAMRA-labeled α3-N203C and α3-N203C-S346G GlyRs, saturating (1 mM) tropisetron induced 
mean ΔFmax responses of +3.3 ± 0.3 and +7.3 ± 0.5 %, respectively (P < 0.05 by unpaired t-test, n = 5 oocytes 
each). As shown in Fig. S3B-E, phosphorylation also reduced the tropisetron-induced ΔFmax response in α3-
N203C GlyRs. 
   The above results are consistent with phosphorylation inducing a conformational change in or near the 
glycine-binding pocket. To determine whether it produces a conformational change inside the pocket, we 
quantified the effect of phosphorylation on the efficacy with which tropisetron, 6-methoxyharmalan and 
harmane inhibited EC20 (40 µM) glycine-activated ΔIs in α3-WT GlyRs. This experiment also avoids the use 
of chemically modified receptors. As shown in Fig. 5A and B, the potency with which 150 µM tropisetron 
and 100 µM 6-methoxyharmalan inhibited α3-WT GlyRs was significantly and reversibly enhanced by 
phosphorylation. In contrast, the inhibition produced by 60 µM harmane was not affected by 
phosphorylation. Consistent with results from the α3-R19’C and α3-N203C GlyRs described above (Fig. 3E, 
4C), glycine-gated ΔIs in α3-WT GlyRs were not affected by phosphorylation. Thus, the results strongly 
suggest that phosphorylation induces a conformational change in the glycine-binding site. 
   Given that S346 phosphorylation inhibits α3-WT GlyRs expressed in mammalian HEK293 cells3,7 but not 
in Xenopus oocytes, it is evident that this effect is expression system-specific. It was therefore relevant to 
determine whether phosphorylation also induces a conformational change in the glycine-binding site of 
HEK293 cell-expressed α3-WT GlyRs. As it is not feasible to perform VCF experiments on HEK293 cells 
due to the high level of non-specific fluorophore labelling, we employed a pharmacological approach only. 
Specifically, we continually monitored the inhibitory potency of a 20 µM (~IC50) concentration of tropisetron 
on EC50 (180 µM) glycine-activated ΔIs before, during and after forskolin treatment. Fig. 6A shows a typical 
recording, together with expanded sections of the traces recorded before and immediately after forskolin 
exposure. It shows that forskolin simultaneously reduced ΔI magnitude and enhanced tropisetron potency. 
Results averaged from 6 cells confirm both effects and demonstrate their reversibility after a 15 min wash 
(Fig. 6B, C). In contrast, when applied to α1-WT GlyRs, forskolin was never observed to elicit a detectable 
response (defined as a >10 % change in current over a 10 min application period) in each of 10 cells in 
which it was examined. As tropisetron is a competitive antagonist, it is possible that its enhanced potency in 
could be due to a phosphorylation-mediated reduction in glycine affinity in HEK293 cells. We tested this 
directly by applying alternating EC50 (180 µM) and EC100 (1 mM) concentrations of glycine to α3-WT GlyRs 
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before, during and after the period of forskolin exposure (Fig. 6D). As forskolin inhibited EC100 currents to a 
significantly greater extent than it inhibited EC50 currents (Fig. 6E), it is evident that glycine sensitivity is 
actually enhanced by phosphorylation. This allows us to conclude that phosphorylation directly alters 
tropisetron potency in α3-WT GlyRs. 
   The main insight of this study is that PKA-dependent phosphorylation of α3 GlyRs produces a 
conformational change that propagates to the glycine-binding site. Three main lines of evidence support our 
conclusion that phosphorylation has indeed taken place. First, forskolin is well known to stimulate cAMP 
accumulation and thus activate PKA in HEK293 cells. Second, the effect of forskolin on ΔF magnitude in 
the α3-R19’C GlyR was similar to that of the phosphorylation-mimicking mutation, S346E (Fig. 3A, C). 
Third, forskolin had no effect on ΔF responses in phosphorylation-deficient α3-R19’C-S346G GlyRs or on 
α1-R19’C GlyRs that do not contain an endogenous PKA phosphorylation site.   
  
   The present study demonstrates two separable effects of phosphorylation on α3 GlyRs. The first effect, 
observed only in HEK293 cell-expressed receptors, is the reduced current magnitude. The fact that we 
observed no effect of phosphorylation on α3 GlyR current magnitudes in Xenopus oocytes was fortuitous 
because it allowed us to eliminate receptor internalization or changes in GlyR open probability as possible 
explanations for our VCF results. Thus, it permitted us to unequivocally conclude that phosphorylation of 
S346 exerts a global conformational change that propagates to the α3 GlyR glycine-binding site.  
   The second effect of phosphorylation, observed in both the HEK293 cell and Xenopus oocyte expression 
systems, is the change in structure at the glycine-binding site. The main lines of evidence in support of this 
are, 1) a phosphorylation-mediated micro-environmental change at a fluorophore attached to loop C of the 
glycine-binding site, and 2) a phosphorylation-mediated enhancement of the inhibitory potency of 
tropisetron. The magnitude of this potency increase was remarkably similar in the oocyte and HEK293 cell 
expression systems. Phosphorylation also enhanced receptor sensitivity to glycine in HEK293 cells (Fig. 6E), 
possibly via a similar mechanism.  
   We speculate that the differential effect of phosphorylation in the two expression systems may be due to 
differences in the expression levels of one or more intracellular signaling molecules. We propose that S346 
phosphorylation, in addition to directly altering glycine-binding site structure, either exposes or occludes a 
binding site for an expression system-specific intracellular signaling molecule. The subsequent alteration in 
binding of this molecule to the α3 GlyR thus results in a glycine current magnitude change in HEK293 cells 
only. The identification of this putative signaling molecule may reveal new therapeutic targets for chronic 
pain. 
   It has previously been shown that phosphorylation by PKA or PKC results in the internalization of both 
recombinant α1 and native neuronal GlyRs 27,28. We cannot rule internalization out as a possible explanation 
for the PKA-dependent inhibition of α3 GlyRs we describe in HEK293 cells. We also note that S337, S349 
and S380 in the M3-M4 domain of the rat α3L GlyR are also strong phosphorylation consensus sites (Fig. 
S1). Although it is possible they may also contribute to the effects of PKA-dependent phosphorylation, they 
were not investigated here given that ablation of the S346 phosphorylation site completely eliminated the 
effects of phosphorylation on α3 GlyR current magnitude 3.  
  There is abundant evidence for phosphorylation-induced conformational changes in pLGICs. For example, 
phosphorylation is known to modify receptor functional properties such as desensitization rate, open 
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probability and surface expression efficiency in 5-HT3Rs29, nAChRs26, GABAARs22-24 and GlyRs30,31. 
However, we are not aware of any evidence for phosphorylation-mediated conformational changes in the 
M2-M3 loop or neurotransmitter-binding sites of any pLGIC. Considering the importance of the M2-M3 
loop and neurotransmitter-binding sites for agonist binding, receptor gating12 and desensitization32, our 
findings suggest that these loci could be important sites for investigating the molecular mechanisms by 
which phosphorylation affects pLGIC structure and function.  
   Our results may also have clinical significance. For example, as detailed in the Introduction, PGE2 inhibits 
α3 GlyRs in spinal nociceptive neurons by phosphorylating S3463, thus providing a paradigm for explaining 
chronic inflammatory pain sensitization5,6. Selective enhancement of α3 GlyRs should therefore produce 
analgesia, and recent evidence indicates that potentiators specific for α3 GlyRs are indeed analgesic in 
animal models of chronic inflammatory and neuropathic pain7. Our finding that the α3 GlyR glycine-binding 
site is forced into a unique configuration in chronic pain implies that it should be possible to design drugs to 
selectively potentiate phosphorylated α3 GlyRs, potentially providing a more precisely targeted analgesic 
therapy. Furthermore, serotonin-1A receptor activation dephosphorylates S346 in α3 GlyRs in brainstem 
respiratory neurons, thereby increasing glycinergic synaptic current magnitude and counteracting opioid-
induced breathing depression33. This implies that drugs that selectively potentiate phosphorylated α3 GlyRs 
may also be efficacious as treatments for opioid-induced breathing disorders.  
   In conclusion, we have demonstrated that structural changes in the M3-M4 domain can impact on the 
conformation of the extracellular domains of a pLGIC receptor. In particular, we have shown that 
phosphorylation of S346 exerts a global conformational change that propagates to the α3 GlyR glycine-
binding site. This finding is important for two reasons. First, it provides the first direct evidence for 
phosphorylation producing extracellular conformational changes in any pLGIC, and thus provides a new 
locus for investigating how phosphorylation modulates the structure and function of these receptors. Second, 
it shows that chronic inflammatory pain is accompanied by a unique conformational change in the α3 GlyR 
glycine-binding site, which raises the possibility of developing analgesic drugs to specifically target disease-
affected receptors.  
 
MATERIALS AND METHODS 
 
Chemicals: MTSR and TAMRA were obtained from Toronto Research Chemicals. Glycine, β-alanine, 
taurine, ivermectin, picrotoxin, strychnine, forskolin, tropisetron, harmane and 6-methoxyharmalan were all 
obtained from Sigma. Glycine, β-alanine, taurine and strychnine were dissolved in water. All other drugs 
were prepared as 20-100 mM stocks in dimethylsulfoxide and kept frozen at -20 oC. From these stocks, 
solutions for experiments were prepared on the day of recording. 
 
Molecular biology: Plasmid DNAs for the human α1 and rat α3L GlyR subunits were kindly provided by 
Prof. Peter Schofield (Neuroscience Research Australia) and Prof. Robert Harvey (University College, 
London), respectively. For Xenopus oocyte recordings, the subunit DNAs were subcloned into pGEMHE, a 
plasmid vector optimized for oocyte expression. The α1 and α3L constructs both incorporated the C41A 
mutation that eliminated the sole uncrosslinked extracellular sulfhydryl group. Site directed mutagenesis was 
performed using the QuikChange mutagenesis kit (Stratagene). Successful incorporation of the mutations 
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was confirmed through automated sequencing of the entire cDNA coding region. Chimeras were constructed 
using a multiple-template-based sequential PCR protocol as recently described34. The join sites between the 
α1 and α3 sequences used to create chimeras Chi1 – Chi6 were located between the following pairs of 
residues: α1 Y223/L224 and α3 Y223/L224 for the N terminal end of M1, and α1 R392/I393 and α3 
R400/A401 for the C terminal end of the M3-M4 loop (Fig. S1). ChiA involved inserting the α3 GlyR 
residues K322 – R400, inclusive, in place of α1 GlyR residues R322 – R392, inclusive. ChiB incorporated 
the reverse domain substitution. 
   Ten micrograms of each cDNA was linearized by NheI or PstI and then purified by PCR-purification kit 
(Qiagen). The capped RNAs were transcribed from cDNA using the Ambion T7 mMessage mMachine kit, 
purified by RNAMinikit (Qiagen) eluted with DNA/RNAase free water and diluted to 200ng/µl for oocyte 
injection. 
 
Oocyte preparation, injection and labeling: Female Xenopus laevis frogs (Xenopus Express) were 
anaesthetized with 5mM MS-222 (Sigma Aldrich) and stage VI oocytes were removed from ovaries and 
washed thoroughly in OR-2 (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES, pH 7.4). The oocytes 
were then incubated in collagenase (Sigma Aldrich) in OR-2 for 2 hr at room temperature, rinsed and stored 
in OR-2 at 18 °C.  
   All oocytes were injected with 10 ng of mRNA into the cytosol. To achieve the high levels of expression 
required for the detection of the fluorescent signal over the background (due to oocyte autofluorescence and 
non-specific binding of the dye) the oocytes were incubated at 18 °C for 3-10 days after injection. The 
incubation solution contained 96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES, 0.6 
mM theophylline, 2.5 mM pyruvic acid, 50 μg/ml gentamycin (Cambrex Corporation) and 5 % horse serum 
(Hycell), at pH 7.4. 
   On the day of recording, the oocytes were transferred into ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 
1.8 mM CaCl2, 5 mM HEPES, pH 7.4) and stored on ice. To label with either MTSR or MTS-TAMRA, 
oocytes were transferred into the labeling solution containing 10 μM of either compound in ND96 for 25 s. 
The oocytes were then washed and stored in ND96 for up to 6 hours before recording. All labeling steps 
were performed on ice.  
 
VCF: We employed an inverted microscope (Eclipse TE300, Nikon Instruments) equipped with a high-Q 
tetramethylrhodamine isothiocyanate filter set (Chroma Technology), a Plan Fluor 40x objective (Nikon 
Instruments) and an H7360-03 photomultiplier detection system (Hamamatsu Photonics) attached to the side 
port of the microscope. An excitation filter wheel including a shutter and an emission filter wheel were 
controlled through a Lambda 10-2 unit (Sutter Instruments). A Lambda LS 175-Watt xenon arc lamp served 
as a light source and was coupled to the microscope via a liquid light guide (Sutter Instruments). The design 
of the custom made recording chamber has been described previously35. An automated perfusion system 
operated by a ValveBank-8 valve controller (AutoMate Scientific) was used for perfusion of the recording 
chamber. Electrodes for two-electrode voltage clamp recordings were filled with 3 M KCl and moved by 
automated ROE-200 micromanipulators coupled to an MPC-200 controller (Sutter Instruments). Cells were 
voltage-clamped at -40 mV and currents were recorded using a Gene Clamp 500B amplifier (Molecular 
Devices). Current and fluorescence traces were acquired at 200 Hz via a Digidata 1322A interface and 
Clampex 9.2 software.  
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HEK293 cell culture: We employed HEK293 cell lines that stably expressed either α1 or α3L GlyRs. 
Generation of these cell lines has previously been described36. Cells were cultured on glass coverslips in 
Dulbecco’s modified Eagle Medium supplemented with G-418 (1 mg/ml), penicillin (100 U/ml), 
streptomycin (100 mg/ml) and 10 % Serum Supreme and maintained at 37 ºC in a 5 % CO2 incubator. 
 
Patch clamp electrophysiology: Cells were viewed using an inverted microscope and currents were 
recorded by whole-cell patch-clamp recording. Cells were perfused by an extracellular solution containing 
(in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES/ NaOH and 10 glucose (pH 7.4 adjusted with 
NaOH). Patch pipettes were fabricated from borosilicate hematocrit tubing (Hirschmann Laborgerate) and 
heat polished. Pipettes had a tip resistance of 1-2 MΩ when filled with the intracellular solution consisting of 
(mM): 145 CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES and 10 EGTA (pH 7.4 adjusted with CsOH). After 
establishment of the whole-cell recording configuration, cells were voltage clamped at -40 mV and 
membrane currents were recorded using an Axopatch 200C and pClamp 10 software (Molecular Devices). 
Currents were filtered at 500 Hz and digitized at 2 KHz. 
   Solutions were applied to cells via gravity forced perfusion and parallel microtubules and manual control 
of this system was achieved via a micromanipulator with a solution exchange time  < 250 ms. Experiments 
were conducted at room temperature (19-22 oC). 
 
Data analysis: EC50 and nH values for ligand-induced activation of ΔI and ΔF signals were obtained using 
the empirical Hill equation, fitted with a non-linear least squares algorithm (SigmaPlot 12.0, Systat 
Software). All results are expressed as mean ± standard error of the mean (S.E.M.) of three or more 
independent experiments. All dose-responses relations were fitted using a nonlinear least squares algorithm 
(Sigmaplot 12.0). Unless otherwise indicated, statistical significance was determined by Student’s t-test with 
p < 0.05 representing significance. 
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SUPPORTING INFORMATION AVAILABLE 
This contains additional tables and figures as described in the text. This information is available free of 
charge via the Internet at http://pubs.acs.org/. 
 
ABBREVIATIONS 
5-HT3R, 5-hydroxytryptamine type-3 receptor; ΔF, change in fluorescence; ΔFmax, maximum change in 
fluorescence; ΔI, change in current; ΔImax, maximum change in current; GABAAR, gamma-aminobutyric acid 
type-A receptor; GluClR, glutamate-gated chloride channel receptor; GlyR, glycine receptor; MTSR, 
rhodamine methanethiosulfonate, MTS-TAMRA, 2-((5(6)-tetramethylrhodamine) carboxylamino)ethyl 
methanethiosulfonate; nAChR, nicotinic acetylcholine receptor;  PGE2, prostaglandin E2; PKA, protein 
kinase A; pLGIC, pentameric ligand-gated ion channel; TM, transmembrane; VCF, voltage-clamp 
fluorometry. 
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FIGURE LEGENDS 
 
Fig. 1. Comparison of fluorescence properties of MTSR-labeled α1-R19’C and α3-R19’C GlyRs. In this and 
all subsequent Fig.s, ΔI and ΔF recordings are shown in black and red, respectively. A. Structural model of 
an α3 GlyR subunit showing R19’, S346 and N203 as main chain atoms in yellow. Other structures indicated 
include the loop C glycine-binding domain (green), the conserved Cys-loop (red) and the M2-M3 domain 
(black). The location of S346 is indicative only as the M3-M4 domain which houses this residue is yet to be 
structurally determined and is displayed here as a dashed loop. The ligand-binding domain (LBD), 
transmembrane domain (TMD) and intracellular domain (ICD) are delineated as indicated. The model was 
generated as recently described 37 and rendered in Pymol. B. Examples of glycine ΔI and ΔF dose-response 
relationships recorded from an oocyte that expressed MTSR-labeled α3-R19’C GlyRs. C. Averaged ΔI and 
ΔF dose-response relations for the MTSR-labeled α3-R19’C GlyR together with the averaged ΔI dose-
response relation for the MTSR-labeled α3-WT GlyR. Mean parameters of best fit to the dose-response 
curves are given in Table S1. D. Sample recordings from α1-R19’C and α3-R19’C GlyRs showing typical 
differences in the magnitude and decay rates of ΔFmax responses. E. Comparison of averaged ΔImax and ΔFmax 
values. F. Comparison of ΔFmax decay rates. In this analysis, the ΔFmax half-decay times were ratioed with the 
corresponding ΔImax half-decay times to normalize for possible differences in ΔI decay rate between α1 and 
α3 GlyRs. *** p < 0.001 compared to the α1-R19’C GlyR by unpaired t-test.  
 
Fig. 2. Comparison of ΔI and ΔF properties of eight chimeras comprized of α1-R19’C and α3-R19’C GlyR 
domains. A. Schematic illustration of the chimera structure. Domains from α1 and α3 GlyRs are colored 
black and red, respectively. Transmembrane α-helices are indicated by boxes with other regions shown as 
solid lines. The location of R19’C is indicated by an orange circle. The locations of the boundaries between 
the α1 and α3 sequences for each chimera are detailed above. Results shown in panels B-D are averaged 
from 5 – 12 oocytes. B. Mean ΔImax values of the indicated constructs. *** p < 0.001 compared to the α1-
R19’C GlyR by unpaired t-test C. Mean ΔFmax values of the indicated constructs. *** p <0.001, ### p <0.001 
compared to α1-R19’C GlyR and α3-R19’C GlyR, respectively, by one way ANOVA followed by 
Dunnett’s post hoc test. D. Mean ∆Fmax/ΔImax half-decay time ratios of the indicated constructs. * p <0.05, # p 
<0.05 compared to α1-R19’C GlyR and α3-R19’C GlyR, respectively, by one way ANOVA followed by 
Dunnett’s post hoc test. 
 
Fig. 3. Effect of phosphorylation on ΔF responses of MTSR-labeled α3-R19’C GlyRs. A. Comparison of 
ΔImax and ΔFmax values in MTSR-labeled α3-R19’C, α3-R19’C-S346E and α3-R19’C-S346G GlyRs. *** p < 
0.001 compared to α3-R19’C GlyR using unpaired t-test. No significant differences were found for current 
magnitudes or for the increase in ΔFmax at the α3-R19’C-S346G GlyRs (P > 0.10). B. Comparison of 
∆Fmax/ΔImax half-decay time ratios in the same three receptors. * p < 0.05 in α3-R19’C-S346G GlyR 
compared to α3-R19’C GlyR using unpaired t-test. There was no significant difference between any other 
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receptor pair (P > 0.10). C. Examples of EC50 glycine-induced ΔI and ΔF responses in MTSR-labeled α3-
R19’C GlyRs before and after a 15 min forskolin (FSK) treatment and after a 15 min wash. D. Examples of 
EC50 glycine-induced ΔI and ΔF responses in MTSR-labeled α3-R19’C-S346G GlyRs before and after a 15 
min forskolin treatment and after a 15 min wash. E. Averaged data for the experiments shown in C and D (all 
n = 5). In addition, the effects of a control 15 min dimethyl sulfoxide (DMSO) treatment and wash on α3-
R19’C GlyRs is also shown (left panel, all n = 4). * p < 0.05, *** p < 0.001 compared to control using paired 
t-test. 
 
Fig. 4. Effects of phosphorylation on ΔF responses induced by glycine and strychnine in MTS-TAMRA-
labeled α3-N203C GlyRs. A. Examples of glycine- and strychnine-induced ΔImax and ΔFmax responses in 
MTS-TAMRA-labeled α3-N203C GlyRs before and after a 15 min forskolin treatment and after a 15 min 
wash. B. Corresponding experiments on MTS-TAMRA-labeled α3-N203C-S346G GlyRs. C. Averaged data 
for the experiments shown in A and B (all n = 5). * p < 0.05, ** p < 0.01, *** p < 0.001 relative to control 
using paired t-test. 
 
Fig. 5. Effects of phosphorylation on the inhibitory potencies of tropisetron, 6-methoxyharmalan and 
harmane in α3-WT GlyRs. A. Examples of the inhibitory effects of ~IC50 concentrations of tropisetron, 6-
methoxyharmalan and harmane on currents activated by EC20 (40 µM) glycine in α3-WT GlyRs before and 
after a 15 min forskolin treatment and a 15 min wash. B. Averaged data for the experiments shown in A (all 
n = 7). The percentage inhibition produced by the drugs under control conditions was expressed as 100 %. 
The fractional increase in inhibition after phosphorylation is indicated by a corresponding reduction in the 
percentage current.   * p < 0.05, ** p < 0.01 relative to control using paired t-test. 
 
Fig. 6. Effects of phosphorylation on α3-WT GlyRs stably expressed in HEK293 cells. A. Upper panel 
shows a continuous recording with downward current deflections representing successive activations by EC50 
(180 µM) glycine, upon each of which is superimposed an ~IC50 (20 µM) concentration of tropisetron. The 
experimental protocol is more readily observed in the two expanded traces below where the glycine and 
tropisetron applications are indicated by filled and unfilled bars, respectively. The centre trace (labeled FSK) 
has been reproduced (right) normalized to the control trace (left) to emphasize the enhanced inhibition by 
tropisetron following forskolin exposure. B. Mean forskolin-induced reduction in current magnitude relative 
to control averaged from 6 cells for the experiment shown in A. Partial reversal of the current inhibition by a 
15 min wash is also shown. Note that 10 cells were employed in this experiment and 4 cells that elicited no 
detectable response to forskolin were excluded from analysis. A detectable response was defined as a >10 % 
change in current over a 10 min forskolin application period. C. Mean forskolin-induced increase in 
tropisetron-mediated inhibition expressed as a percentage of the control inhibition for the experiment shown 
in A. All results were averaged from the same 6 cells as analysed in B. D. Upper panel shows a continuous 
recording of current activations induced by alternating applications of EC50 (150 µM) and EC100 (1 mM) 
glycine. Two sections of this recording are shown expanded below to illustrate the change in magnitudes of 
the currents following forskolin exposure. E. Mean forskolin-induced changes in EC50 and EC100 glycine 
current magnitudes relative to control. A total of 7 cells was investigated here with 3 eliciting no detectable 
response to forskolin. Thus, the results represent the average of 4 cells. * p < 0.05, ** p < 0.01, *** p < 
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0.001 relative to control using paired t-test.    
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Supplementary Information 
 
Table S1  
Summary of results for agonist-activated ΔI and ΔF responses at unlabeled and MTSR-labeled α1-R19’C 
and α3-R19’C GlyRs. Electrophysiological and fluorescence data are shown in normal and bold type, 
respectively. 
 
 
 
Agonist Construct EC50  (µM) nH Imax (µA) ΔFmax (%) 
ΔF half decay time /ΔI half decay time n 
glycine 
α3-WT unlabeled 74 ± 2 2.9 ± 0.2 5.4 ± 0.6 - - 6 
α3-WT labeled 71 ± 2 2.9 ± 0.2 5.6 ± 0.5 - 
- 
6 
α3-WT labeled ΔF - - - 0 6 
α3-19’C unlabeled 12700 ± 600a 1.4 ± 0.1a 1.7 ± 0.1a - - 7 
α3-19’C labeled 1740 ± 270ab 1.2 ± 0.1a 3.1 ± 0.3a - 
5.1 ± 1.0 
13 
α3-19’C labeled ΔF 1340 ± 210 1.1 ± 0.1 - 5.4 ± 0.5 13 
α1-WT unlabeled 17.9 ± 1.5a 2.8 ± 0.1 4.8 ± 0.4 - - 4 
α1-WT labeled 17.1 ± 0.6a 2.8 ± 0.2 4.9 ± 0.7 - - 
 
4 
α1-WT labeled ΔF - - - 0 4 
α1-19’C unlabeled 4320 ± 220a 1.3 ± 0.1a 2.3 ± 0.4a - - 5 
α1-19’C labeled 499 ± 79ab 1.2 ± 0.2a 3.6 ± 0.6a NA 
1.0 ± 0.1 
6 
α1-19’C labeled ΔF 1110 ± 100c 1.0 ± 0.1 - 23 ± 4 6 
β-alanine 
α3-19’C labeled 2610 ± 940a 1.5 ± 0.3a 0.4 ± 0.05a NA 
4.7 ± 0.7 
5 
α3-19’C labeled ΔF 22100 ± 2300c 1.1 ± 0.1 - 2.6 ± 0.5 5 
taurine 
α3-19’C labeled - - 0.03 ± 0.01a - 
- 
5 
α3-19’C labeled ΔF 5990 ± 780 1.3 ± 0.4 - 1.3 ± 0.2 5 
 
a - significant difference to electrophysiological properties of glycine-activated unlabeled α3-WT GlyRs 
(Student’s t-test, p < 0.05) 
b - significant difference to electrophysiological properties before labeling in the same mutant GlyR 
(Student’s t-test, p < 0.05)  
c - significant difference of fluorescence properties to electrophysiological properties after labeling in the 
same mutant GlyR (Student’s t-test, p < 0.05) 
α1-WT data are reproduced from (36)  
Table S2 
Summary of results for glycine-activated ΔI and ΔF responses at chimeric and double mutant GlyRs 
incorporating MTSR labels at R19’C. Electrophysiological and fluorescence data are shown in normal and 
bold type, respectively. 
 
 
 
 
 
 
 
 
There was no significant difference among the EC50, nH or ΔImax data using one way ANOVA followed by 
Dunnett’s post hoc test. A statistical analysis of ΔFmax and ΔF/ΔI half decay ratio data is presented in Fig. 3.  
 
 
 
Construct EC50  (µM) nH Imax (µA) ΔFmax (%) 
ΔF half decay time /ΔI half decay time n 
Chi1 unlabeled 2880 ± 390 3.2 ± 0.2 1.6 ± 0.5 - - 5 
Chi1 labeled 860 ± 490 1.1 ± 0.1 2.4 ± 0.5 - 3.2 ± 0.3b 5 Chi1 ΔF 1450 ±  310 1.3 ± 0.2 - 2.3 ± 0.2b 5 
Chi2 unlabeled 2330 ±520 2.7 ± 0.1 3.2 ± 0.4 - - 5 
Chi2 labeled 530 ± 160 1.1 ± 0.01 2.6 ± 0.4 - 4.2 ± 0.8b 6 Chi2 ΔF 970 ±  350 0.9 ± 0.3 - 4.8 ± 0.2b 6 
Chi3 unlabeled 5710 ± 1020 1.3 ± 0.1 1.4 ± 0.1 - 
- 
 5 
Chi3 labeled 610 ± 30 1.8 ± 0.2 3.0 ± 0.2 - 1.0 ± 0.1a 6 Chi3 ΔF 1000 ±  190 1.3 ± 0.1 - 18.5 ± 3.3a 6 
Chi4 unlabeled 5300 ± 220 1.7 ± 0.1 1.9 ± 0.04 - - 4 
Chi4 labeled 770 ± 80 1.2 ± 0.03 2.8 ± 0.3 - 5.7 ± 1.6b 5 Chi4 ΔF 640 ±  60 1.3 ± 0.05 - 4.4 ± 0.2b 5 
Chi5 unlabeled 3840 ± 340 1.6 ± 0.1 3.2 ± 0.2 - - 5 
Chi5 labeled 500 ± 40 2.0 ± 0.3 2.5 ± 0.3 - 1.2 ± 0.2a 5 Chi5 ΔF 980 ±  210 1.3 ± 0.02 - 23.4 ± 3.7a 5 
Chi6 unlabeled 5640 ± 250 1.8 ± 0.2 3.0 ± 0.5 - - 5 
Chi6 labeled 630 ± 240 2.1 ± 0.4 2.4 ± 0.4 - 0.7 ± 0.01a 5 Chi6 ΔF 1140 ±  190 1.0 ± 0.2 - 20.4 ± 3.2a 5 
ChiA unlabeled 10800 ± 610 1.1 ± 0.1 1.1 ± 0.3 - - 5 
ChiA labeled 780 ± 140 2.0 ± 0.3 0.9 ± 0.1 - 3.5 ± 0.4b 7 ChiA ΔF 920 ±  240 0.8 ± 0.1 - 3.1 ± 0.5b 7 
ChiB unlabeled 3650 ± 920 1.8 ± 0.2 2.4 ± 0.6 - - 6 
ChiB labeled 410 ± 60 1.5 ± 0.2 2.6 ± 0.3 - 1.0 ± 0.1a 7 ChiB ΔF 1150 ±  190 1.3 ± 0.2 - 21.9 ± 3.4a 7 
α3-R19’C,S346G unlabeled 6420 ± 370 1.5 ± 0.03 2.1 ± 0.2 - - 5 
α3-R19’C,S346G labeled 710 ± 40 1.4 ± 0.05 2.8 ± 0.3 - 1.8 ± 0.5a 5 
α3-R19’C,S346G ΔF 880 ±  210 1.3 ± 0.2 - 6.7 ± 0.5 5 
α3-R19’C,S346E unlabeled 8890 ± 280 1.8 ± 0.1 1.5 ± 0.1 - - 5 
α3-R19’C,S346E labeled 800 ± 70 1.4 ± 0.1 2.4 ± 0.1 - 3.7 ± 1.1b 5 
α3-19’C,S346E ΔF 1230 ±  350 1.1 ± 0.1 - 2.2 ± 0.1 5 
Table S3  
Summary of results for agonist-activated ΔI and ΔF responses at MTS-TAMRA-labeled N203C mutant 
GlyRs. Electrophysiological and fluorescence data are shown in normal and bold type, respectively.  
 
 
  
Construct EC50  (µM) nH Imax (µA) ΔFmax (%) n 
α3-N203C  
ΔI glycine 57 ± 8 2.5 ± 0.2 4.9 ± 0.2 - 5 
α3-N203C  
ΔF glycine 732 ± 24 1.0 ± 0.1 - 4.0 ± 0.4 5 
α3-N203C  
ΔF strychnine - - - 5.5 ± 0.3 5 
α3-N203C-S346G 
ΔI glycine 43 ± 5 2.3 ± 0.2 4.7 ± 0.2 - 5 
α3-N203C-S346G   
ΔF glycine 588 ± 35 1.2 ± 0.2 - 7.1 ± 0.5 5 
α3-N203C-S346G   
ΔF strychnine - - - 8.4 ± 0.2 5 
 
 
  
 
Fig. S1. Amino acid sequence alignment of the coding region of the human α1 GlyR subunit (Uniprot 
accession number: P23415-2, isoform b) and the rat α3L GlyR subunit (Uniprot accession number: P24524).  
The alignment was generated using ClustalW. The residues that were mutated in this study are shown in blue. 
In addition to S346, the residues shown in red are also predicted to be serine phosphorylation sites according 
to the NetPhos 2.0 Server. Orange vertical lines denote the locations of subunit join sites used in creating 
α1−α3 chimeras.   
Human_alpha1  ARSAPKPMSPSDFLDKLMGRTSGYDARIRPNFKGPPVNVSCNIFINSFGS 50
  Rat_alpha3L ARSRSAPMSPSDFLDKLMGRTSGYDARIRPNFKGPPVNVTCNIFINSFGS 50
              *** . *********************************:**********
Human_alpha1  IAETTMDYRVNIFLRQQWNDPRLAYNEYPDDSLDLDPSMLDSIWKPDLFF 100
  Rat_alpha3L IAETTMDYRVNIFLRQKWNDPRLAYSEYPDDSLDLDPSMLDSIWKPDLFF 100
              ****************:********.************************
Human_alpha1  ANEKGAHFHEITTDNKLLRISRNGNVLYSIRITLTLACPMDLKNFPMDVQ 150
  Rat_alpha3L ANEKGANFHEVTTDNKLLRIFKNGNVLYSIRLTLTLSCPMDLKNFPMDVQ 150
              ******:***:********* :*********:****:*************
Human_alpha1  TCIMQLESFGYTMNDLIFEWQEQGAVQVADGLTLPQFILKEEKDLRYCTK 200
  Rat_alpha3L TCIMQLESFGYTMNDLIFEWQDEAPVQVAEGLTLPQFLLKEEKDLRYCTK 200
              *********************::..****:*******:************
Human_alpha1  HYNTGKFTCIEARFHLERQMGYYLIQMYIPSLLIVILSWISFWINMDAAP 250
  Rat_alpha3L HYNTGKFTCIEVRFHLERQMGYYLIQMYIPSLLIVILSWVSFWINMDAAP 250
              ***********.***************************:**********
Human_alpha1  ARVGLGITTVLTMTTQSSGSRASLPKVSYVKAIDIWMAVCLLFVFSALLE 300
  Rat_alpha3L ARVALGITTVLTMTTQSSGSRASLPKVSYVKAIDIWMAVCLLFVFSALLE 300
              ***.**********************************************
Human_alpha1  YAAVNFVSRQHKELLRFRRKRR-HHK-------------EDEAGEGRFNF 336
  Rat_alpha3L YAAVNFVSRQHKELLRFRRKRKNKTEAFALEKFYRFSDTDDEVRESRLSF 350
              *********************: : :             :**. *.*:.*
Human_alpha1  SAYGMGPACLQAKDGISVKGANNSNTTNPPPAPSKSPEEMRKLFIQRAKK 386
  Rat_alpha3L TAYGMGP-CLQAKDGVVPKGPNHAVQVMP-----KSADEMRKVFIDRAKK 394
              :****** *******:  **.*::  . *     **.:****:**:****
Human_alpha1  IDKISRIGFPMAFLIFNMFYWIIYKIVRREDVHNQ-- 422
  Rat_alpha3L IDTISRACFPLAFLIFNIFYWVIYKILRHEDIHHQQD 431
              **.***  **:******:***:****:*:**:*:*
 
 
Fig. S2. Pharmacological characterization of MTSR-labeled α3-R19’C GlyRs. A. Sample ΔImax and ΔFmax 
recordings in response to consecutive applications of saturating taurine (tau) and glycine (gly, left panel) or 
saturating β-alanine (β-ala) and glycine (right panel). Gray bars indicate duration of applications of taurine 
and β-alanine. B. Averaged ΔI and ΔF dose-response relationships for glycine, taurine and β-alanine. All 
dose-response curves are normalised to those of glycine as measured in the same oocyte. Mean parameters of 
best fit to all dose-response curves are presented in Table S1. C. Sample ΔImax and ΔFmax recordings in 
response to saturating applications of glycine (black bar) and ivermectin (ivm, gray bar). This recording is 
representative of 5 others in which no detectable ivermectin-induced ΔF was observed. D. Sample ΔImax and 
ΔFmax recordings in response to the application of picrotoxin (ptx) alone (left) or co-application of EC50 
glycine with saturating picrotoxin (right). E. Sample ΔImax and ΔFmax recordings in response to application of 
strychnine (str) alone (left) or co-application of EC50 glycine with saturating strychnine (right). Averaged 
values for experiments in panels D and E are given in the main text.  
 
 
 
Fig. S3. Effects of phosphorylation on ΔFmax responses induced by tropisetron, 6-methoxyharmalan and 
harmane in MTS-TAMRA-labeled α3-N203C GlyRs. A. Structures of the three molecules. B. Examples of 
ΔFmax responses induced by 1 mM tropisetron (trop), 200 µM 6-methoxyharmalan (6-mh) and 200 µM 
harmane (har) on MTS-TAMRA-labeled α3-N203C GlyRs before and after a 15 min forskolin (FSK) 
treatment and a 15 min wash. C. Corresponding experiments on MTS-TAMRA-labeled α3-N203C-S346G 
GlyRs. D. Averaged data for the experiments shown in B and C (all n = 6). * p < 0.05, ** p < 0.01, *** p < 
0.001 relative to control using paired t-test. 
 
 
